Sheldon H. Preskorn
#156,253
Most Influential Person Across History
Sheldon H. Preskorn's AcademicInfluence.com Rankings
Download Badge
Medical Philosophy
Why Is Sheldon H. Preskorn Influential?
(Suggest an Edit or Addition)Sheldon H. Preskorn's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A functional anatomical study of unipolar depression (1992) (1285)
- An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder (2008) (485)
- Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors (1997) (369)
- Evidence of the dual mechanisms of action of venlafaxine. (2000) (260)
- Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression (2004) (259)
- Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. (1991) (208)
- Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) (2019) (206)
- Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. (1994) (195)
- Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. (1998) (166)
- Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. (1995) (160)
- Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. (2015) (156)
- Migraine prophylaxis. A comparison of propranolol and amitriptyline. (1987) (145)
- Fluoxetine impairs clearance of alprazolam but not of clonazepam (1992) (135)
- Drug-drug interactions. (1996) (131)
- Normalizing Effects of EVP-6124, an Alpha-7 Nicotinic Partial Agonist, on Event-Related Potentials and Cognition: A Proof of Concept, Randomized Trial in Patients with Schizophrenia (2014) (124)
- Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. (1997) (121)
- Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. (1996) (118)
- Antidepressant drug selection: criteria and options. (1994) (117)
- Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. (2010) (111)
- Clinical and demographic factors associated with DSM-IV melancholic depression. (2006) (110)
- Tricyclic antidepressant-induced seizures and plasma drug concentration. (1992) (110)
- Benzodiazepines and withdrawal psychosis. Report of three cases. (1977) (109)
- Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance. (1996) (105)
- The SSRIs: advantages, disadvantages and differences (1995) (104)
- Central Nervous System Toxicity of Tricyclic Antidepressants: Phenomenology, Course, Risk Factors, and Role of Therapeutic Drug Monitoring (1990) (99)
- Recent pharmacologic advances in antidepressant therapy for the elderly. (1993) (97)
- Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. (2013) (96)
- Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial (2018) (96)
- Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. (2001) (94)
- Therapeutic Drug Monitoring of Antidepressants (1999) (92)
- Toxicity of tricyclic antidepressants--kinetics, mechanism, intervention: a review. (1982) (91)
- Sertraline 50 mg daily: the optimal dose in the treatment of depression. (1995) (91)
- Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. (1993) (89)
- Examining Concentration-Dependent Toxicity of Clozapine: Role of Therapeutic Drug Monitoring (2005) (87)
- Brain concentrations of tricyclic antidepressants: Single-dose kinetics and relationship to plasma concentrations in chronically dosed rats (2004) (83)
- Polypharmacy: When Is It Rational? (2007) (82)
- Comparison of Duloxetine, Escitalopram, and Sertraline Effects on Cytochrome P450 2D6 Function in Healthy Volunteers (2007) (81)
- Comparison of the Pharmacokinetics of Venlafaxine Extended Release and Desvenlafaxine in Extensive and Poor Cytochrome P450 2D6 Metabolizers (2009) (81)
- Depression in children: relationship between plasma imipramine levels and response. (1982) (79)
- Therapeutic drug monitoring. Principles and practice. (1993) (77)
- Plasma levels of imipramine and adverse effects in children. (1983) (72)
- Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2×2 clinical trial (2012) (72)
- Pharmacokinetics of antidepressants: why and how they are relevant to treatment. (1993) (72)
- Depression in prepubertal children: dexamethasone nonsuppression predicts differential response to imipramine vs. placebo. (1987) (70)
- Serious adverse effects of combining fluoxetine and tricyclic antidepressants. (1990) (69)
- The effect of concomitant disorders in childhood depression on predicting treatment response. (1990) (68)
- A Thorough QTc Study of 3 Doses of Iloperidone Including Metabolic Inhibition Via CYP2D6 and/or CYP3A4 and a Comparison to Quetiapine and Ziprasidone (2013) (65)
- Therapeutic drug monitoring of tricyclic antidepressants. (1988) (64)
- Fluoxetine Pharmacokinetics and Effect on CYP2C19 in Young and Elderly Volunteers (2001) (63)
- Somatic therapy for major depressive disorder: selection of an antidepressant. (1992) (63)
- Exposure‐Response Analysis in Patients With Schizophrenia to Assess the Effect of Asenapine on QTc Prolongation (2009) (62)
- Complexity of Medication Use in the Veterans Affairs Healthcare System: Part I: Outpatient Use in Relation to Age and Number of Prescribers (2005) (60)
- Central adrenergic regulation of cerebral microvascular permeability and blood flow; anatomic and physiologic evidence. (1980) (59)
- 2010 guide to psychiatric drug interactions (2004) (57)
- Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a Roadmap. (2007) (56)
- Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. (1997) (56)
- Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. (1994) (54)
- Guide to Psychiatric Drug Interactions (2006) (54)
- The economic consequences of a drug-drug interaction. (2001) (53)
- Complexity of Medication Use in the Veterans Affairs Healthcare System: Part II. Antidepressant Use Among Younger and Older Outpatients (2005) (53)
- Reproducibility of the In Vivo Effect of the Selective Serotonin Reuptake Inhibitors on the In Vivo Function of Cytochrome P450 2D6: An Update (Part I) (2003) (52)
- Medical therapies for mood disorders alter the blood-brain barrier. (1981) (52)
- Antidepressant response and plasma concentrations of bupropion. (1983) (51)
- Evaluation of Bupropion Hydrochloride: The First of a New Class of Atypical Antidepressants (1984) (50)
- The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. (1996) (49)
- Pharmacokinetics of Venlafaxine Extended Release 75 mg and Desvenlafaxine 50 mg in Healthy CYP2D6 Extensive and Poor Metabolizers (2011) (49)
- Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. (1996) (49)
- Plasma levels of amitriptyline: effect of age and sex. (1985) (48)
- The effect of diethyldithiocarbamate on brain uptake of cadmium. (1982) (48)
- The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. (2009) (47)
- Fatality associated with combined fluoxetine-amitriptyline therapy. (1997) (46)
- Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: an update (part II). (2003) (46)
- The Potential for Clinically Significant Drug-Drug Interactions Involving the CYP 2D6 System: Effects with Fluoxetine and Paroxetine versus Sertraline (2007) (46)
- Tricyclic antidepressants: the whys and hows of therapeutic drug monitoring. (1989) (45)
- Venlafaxine Metabolism as a Marker of Cytochrome P450 Enzyme 2D6 Metabolizer Status (2009) (45)
- Critical issues in the treatment of affective disorders (1995) (43)
- Antidepressant Treatment and Altered CYP2D6 Activity: Are Pharmacokinetic Variations Clinically Relevant? (2011) (42)
- Serotonin Syndrome Induced by Venlafaxine and Fluoxetine: A Case Study in Polypharmacy and Potential Pharmacodynamic and Pharmacokinetic Mechanisms (1998) (42)
- The effect of dibenzazepines (tricyclic antidepressants) on cerebral capillary permeability in the rat in vivo. (1980) (41)
- A possible bupropion and imipramine interaction. (1997) (41)
- Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open‐label, crossover studies (2013) (41)
- Tricyclic-antidepressant-induced delirium and plasma drug concentration. (1982) (41)
- Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline (1994) (40)
- What predicts attrition in second step medication treatments for depression?: a STAR*D Report. (2009) (40)
- The Overlap of DSM-IV Syndromes: Potential Implications for the Practice of Polypsychopharmacology, Psychiatric Drug Development, and the Human Genome Project (2002) (40)
- CNS drug development. Part I: The early period of CNS drugs. (2010) (38)
- Correlation of serum and salivary cortisol levels in prepubertal school-aged children. (1988) (38)
- Should bupropion dosage be adjusted based upon therapeutic drug monitoring? (1991) (37)
- Retarded tumor growth and greater longevity in mice after fetal irradiation by 2450‐MHz microwaves (1978) (37)
- Mania triggered by a steroid nasal spray in a patient with stable bipolar disorder. (1989) (36)
- Effect of Desvenlafaxine on the Cytochrome P450 2D6 Enzyme System (2008) (35)
- Selective Serotonin Reuptake Inhibitors (2004) (35)
- Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future (2006) (33)
- Debate resolved: there are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes (1998) (33)
- Attention-Deficit and Disruptive Behavior Disorders (2014) (33)
- Classification of Neuropsychiatric Medications by Principal Mechanism of Action: A Meaningful Way to Anticipate Pharmacodynamically Mediated Drug Interactions (Part II) (2003) (33)
- A Study of the Potential Effect of Sertraline on the Pharmacokinetics and Protein Binding of Tolbutamide (1997) (33)
- The Evolution of Antipsychotic Drug Therapy: Reserpine, Chlorpromazine, and Haloperidol (2007) (33)
- Psychopathology in families of children with major depressive disorders. (1994) (32)
- Effect of Study Criteria on Recruitment and Generalizability of the Results (2005) (32)
- Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. (1994) (32)
- Lurasidone drug-drug interaction studies: a comprehensive review (2014) (32)
- The dexamethasone suppression test in prepubertal depressed children. (1985) (32)
- Pharmacokinetics and Therapeutics of Acute Intramuscular Ziprasidone (2005) (32)
- Subtype (2020) (32)
- Role of the central adrenergic system in mediating amitriptyline-induced alteration in the mammalian blood-brain barrier in vivo. (1982) (32)
- The 5% of the Population at High Risk for Severe COVID-19 Infection Is Identifiable and Needs to Be Taken Into Account When Reopening the Economy (2020) (31)
- Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified-release products: workshop summary report. (2010) (31)
- Steady-state plasma imipramine levels in prepubertal depressed children. (1982) (31)
- Selection of an antidepressant: mirtazapine. (1997) (31)
- Central adrenergic regulation of cerebral microvascular permeability and blood flow: pharmacologic evidence. (1980) (31)
- Nefazodone pharmacokinetics in depressed children and adolescents. (2000) (30)
- Liquid chromatography of amitriptyline and related tricyclic compounds. (1980) (30)
- Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. (1997) (30)
- Antidepressants alter cerebrovascular permeability and metabolic rate in primates. (1982) (29)
- Pharmacokinetics of Venlafaxine Extended Release 75 mg and Desvenlafaxine 50 mg in Healthy CYP 2 D 6 Extensive and Poor Metabolizers A Randomized , Open-Label , Two-Period , Parallel-Group , Crossover Study (2012) (29)
- Effect of Sertraline on the Pharmacokinetics and Protein Binding of Diazepam in Healthy Volunteers (1997) (29)
- Plasma levels of imipramine and metabolites in 68 hospitalized children. (1989) (29)
- The dexamethasone suppression test in hospitalized prepubertal depressed children. (1984) (28)
- Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. (1995) (28)
- Detrimental Antidepressant Drug–Drug Interactions: Are They Clinically Relevant? (2006) (27)
- Comparison of the Parent and Child Versions of the Children's Depression Inventory (CDI) (1991) (27)
- Results of the STAR*D Study: Implications for Clinicians and Drug Developers (2009) (26)
- Mania during fluoxetine treatment for recurrent depression. (1989) (26)
- Antidepressant Response and Plasma Concentrations of Fluoxetine (1991) (26)
- Antipsychotic drug development in the pre-human-genome era: a full circle. (2001) (25)
- How Biomarkers Will Change Psychiatry: From Clinical Trials to Practice. Part I Introduction (2012) (25)
- Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics? (1995) (25)
- Antidepressant Drug-Drug Interactions: Clinical Relevance and Risk Management (2007) (24)
- Therapeutic Drug Monitoring (TDM) in Psychiatry (Part I): Why Studies Attempting to Correlate Drug Concentration and Antidepressant Response Don’t Work (2014) (24)
- Pseudohypoparathyroidism and Capgras Syndrome (1978) (24)
- Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial. (2022) (24)
- Psychotropic drugs and alcohol: Pharmacokinetic and pharmaco dynamic interactions (1984) (23)
- A dual label radiotracer technique for the simultaneous measurement of cerebral blood flow and the single-transit cerebral extraction of diffusion-limited compounds in rats (1982) (23)
- Milnacipran: A Dual Norepinephrine and Serotonin Reuptake Pump Inhibitor (2004) (23)
- Cerebral blood flow and cerebrovascular permeability in an inescapable shock (learned helplessness) animal model of depression (1984) (23)
- CNS drug development: Part II: Advances from the 1960s to the 1990s. (2010) (22)
- Depression in children: concentration-dependent CNS toxicity of tricyclic antidepressants. (1988) (22)
- The Stages of Drug Development and the Human Genome Project: Drug Discovery (2000) (22)
- How Sequential Studies Inform Drug Development: Evaluating the Effect of Food Intake on Optimal Bioavailability of Ziprasidone (2010) (22)
- Multiple Medication Use in Patients Seen in the Veterans Affairs Healthcare System: So What? (2005) (21)
- Antidepressants: Past, Present and Future (2004) (20)
- Drug-Drug Interactions: Proof of Relevance (Part I) (2005) (20)
- Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. (1994) (20)
- Twenty Percent of a Representative Sample of Patients Taking Bupropion Have Abnormal, Asymptomatic Electroencephalographic Findings (2010) (20)
- Reboxetine: A Norepinephrine Selective Reuptake Pump Inhibitor (2004) (20)
- The Use of Biomarkers in Psychiatric Research: How Serotonin Transporter Occupancy Explains the Dose-Response Curves of SSRIs (2012) (20)
- Intramuscular Haloperidol or Lorazepam and QT Intervals in Schizophrenia (2004) (20)
- Followup of adolescents initially treated for prepubertal-onset major depressive disorder with imipramine. (1990) (20)
- Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. (2004) (19)
- Classification of neuropsychiatric medications by principal mechanism of action: a meaningful way to anticipate pharmacodynamically mediated drug interactions. (2003) (19)
- Fatal Drug-Drug Interaction As a Differential Consideration in Apparent Suicides (2002) (19)
- Clinically Important Differences in the Pharmacokinetics of the Ten Newer “Atypical” Antipsychotics: Part 1 (2012) (18)
- Understanding Outliers on the Usual Dose-Response Curve: Venlafaxine as a Way to Phenotype Patients in Terms of Their CYP 2D6 Status and Why It Matters (2010) (18)
- The human genome project and drug discovery in psychiatry: identifying novel targets. (2001) (18)
- Beyond signs and symptoms: the case against a mixed anxiety and depression category. (1993) (18)
- Antidepressants: Neurochemical, Behavioral, and Clinical Perspectives (1983) (18)
- Relating clinical trials to psychiatric practice: part I: the case of a 13-year old on aripiprazole and fluoxetine. (2003) (18)
- Self-report vs. biological markers in assessment of childhood depression. (1988) (18)
- Virus-cell interaction in oligodendroglia, astroglia and phagocyte in progressive multifocal leukoencephalopathy (1976) (17)
- What do the terms "drug-specific response/remission rate" and "placebo" really mean? (2011) (17)
- The effect of tricyclic antidepressants on cerebral fluid dynamics. (1979) (17)
- The Relationship Between Adverse Events During Selective Serotonin Reuptake Inhibitor Treatment for Major Depressive Disorder and Nonremission in the Suicide Assessment Methodology Study (2011) (17)
- Treatment Options for the Patient Who Does Not Respond Well to Initial Antidepressant Therapy (2009) (17)
- The Future and Psychopharmacology: Potentials and Needs (1990) (17)
- Drug approvals and withdrawals over the last 60 years. (2002) (17)
- The Human Genome Project and Modern Drug Development in Psychiatry (2000) (17)
- Complexities of Personalized Medicine: How Genes, Drug-Drug Interactions, Dosing Schedules, and Other Factors Can Combine to Produce Clinically Meaningful Differences in a Drug’s Effect (2013) (16)
- Progressive multifocal leukoencephalopathy presenting as focal mass lesion in the brain. (1977) (16)
- An Intravenous Technique for the Measurement of Cerebral Vascular Extraction Fraction in the Rat (1982) (16)
- Results compared for tricyclic antidepressants as assayed by liquid chromatography and enzyme immunoassay. (1988) (16)
- Bilateral altitudinal anopia caused by infarction of the calcarine cortex (1976) (16)
- Lack of sertraline efficacy probably due to an interaction with carbamazepine. (2000) (16)
- Neuroscience Basis of Clinical Depression: Implications for Future Antidepressant Drug Development (2009) (15)
- Clinically Relevant Pharmacology of Neuropsychiatric Drugs Approved Over the Last Three Years: Part II (2006) (15)
- The Adverse Effect Profiles of the Selective Serotonin Reuptake Inhibitors: Relationship to In Vitro Pharmacology (2000) (15)
- CNS Drug Development: Part III Future Directions (2011) (15)
- A Way of Conceptualizing Benzodiazepines to Guide Clinical Use (2015) (15)
- Nortriptyline pharmacokinetics and plasma levels: implications for clinical practice. (1985) (15)
- Patients who do not respond to the "usual" dose: why Terry fell off the dose-response curve. (2009) (15)
- Clinically Important Differences in the Pharmacokinetics of the Ten Newer “Atypical” Antipsychotics: Part 3. Effects of Renal and Hepatic Impairment (2012) (15)
- Use of tricyclic antidepressant blood levels. (1978) (14)
- CYP 2D6 PM Status and Antidepressant Response to Nortriptyline and Venlafaxine: Is It More Than Just Drug Metabolism? (2011) (14)
- Tricyclic‐Induced Electroencephalogram Abnormalities and Plasma Drug Concentrations (1984) (14)
- How Pharmacogenomics (PG) Are Changing Practice: Implications for Prescribers, Their Patients, and the Healthcare System (PG Series Part I) (2013) (13)
- Amitriptyline normalizes tetrabenazine-induced changes in cerebral microcirculation (1986) (13)
- Ketamine: The Hopes and the Hurdles (2012) (13)
- Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study (2019) (13)
- General Principles of Pharmacokinetics (2004) (13)
- Clinically Important Differences in the Pharmacokinetics of the Ten Newer “Atypical” Antipsychotics: Part 2. Metabolism and Elimination (2012) (13)
- Substance dependence. (1998) (13)
- Practical Application of Therapeutic Drug Monitoring: A Tale of Two Patients (2008) (13)
- Clinical application of the concept of relative potency: an example involving chlorpromazine and haloperidol. (2005) (13)
- PHARMACOKINETICS OF PSYCHOTROPIC AGENTS : WHY AND HOW THEY ARE RELEVANT TOTREATMENT (1993) (13)
- Phase I Trials: From Traditional to Newer Approaches Part II (2011) (13)
- How Commonly Used Inclusion and Exclusion Criteria in Antidepressant Registration Trials Affect Study Enrollment (2015) (13)
- Clinical pharmacology in the development of new antidepressants: the challenges. (2014) (13)
- Tianeptine: A Facilitator of the Reuptake of Serotonin and Norepinephrine as an Antidepressant? (2004) (13)
- Increase in plasma levels of clozapine and norclozapine after administration of nefazodone. (2001) (12)
- How drug-drug interactions can impact managed care. (2004) (12)
- Cerebromicrocirculatory defects in animal model of depression (1984) (12)
- Therapeutic drug monitoring of bupropion. (1990) (12)
- Dexamethasone suppression test and clinical outcome in prepubertal depressed children. (1986) (11)
- Bupropion Plasma Levels Intraindividual and Interindividual Variability (1989) (11)
- How Adaptive Trial Designs can Increase Efficiency in Psychiatric Drug Development: A Case Study. (2011) (11)
- Polypharmacy in a Patient with Refractory Major Depression: Part I: The Case (2002) (11)
- Dosage schedule and plasma levels of doxepin and desmethyldoxepin. (1978) (11)
- Comments on the role of therapeutic drug monitoring for clozapine. (2005) (11)
- Factors Associated with Concomitant Psychotropic Drug Use in the Treatment of Major Depression: A STAR*D Report (2009) (11)
- The Package Insert: Who Writes It and Why, What Are Its Implications, and How Well Does Medical School Explain It? (2014) (11)
- Why the Transdermal Delivery of Selegiline (6 Mg/24 Hr) Obviates the Need for a Dietary Restriction on Tyramine (2006) (11)
- Should rational drug development in psychiatry target more than one mechanism of action in a single molecule (1995) (11)
- The Effect of Mineralocorticoid and Glucocorticoid Receptor Antagonism on Autobiographical Memory Recall and Amygdala Response to Implicit Emotional Stimuli (2016) (11)
- Beyond DSM-IV: What is the Cart and What is the Horse? (1995) (11)
- Neuroleptic Malignant Syndrome Resulting from a Complex Drug-Drug Interaction: "I Don't See 'Em!" (2007) (10)
- Drug development in psychiatry and genomics: from E. coli to man. (2001) (10)
- Therapeutic drug monitoring of tricyclic antidepressants: a standard of care issue. (1989) (10)
- How Biomarkers Will Change Psychiatry. Part II: Biomarker Selection and Potential Inflammatory Markers of Depression (2012) (10)
- The difference between the formal and the functional dose: the case of the patient on thioridazine and fluvoxamine. (2005) (10)
- Pharmacotherapeutic profile of venlafaxine (1997) (10)
- Sleeplessness (1885) (10)
- Multiple medications, multiple considerations. (2001) (10)
- Multiple Medication Use Presenting as Parkinson's Dementia Complex: A Message from Titanic (2008) (10)
- Reducing the risk of drug-drug interactions: a goal of rational drug development. (1996) (10)
- Mania induced by metoclopramide: case report. (1984) (10)
- Lack of effect of sertraline on the pharmacokinetics of alprazolam. (2000) (10)
- Imipramine vs. placebo studies of childhood depression: baseline predictors of response to treatment and factor analysis of presenting symptoms. (1988) (10)
- Phase I trials: from traditional to newer approaches. Part I. (2011) (10)
- Progressive multifocal leukoencephalopathy: cerebral mass lesions. (1979) (10)
- Imipramine and desipramine plasma levels: relationship to dosage schedule and sampling time. (1978) (10)
- Psychotropic drugs and alcohol: pharmacokinetic and pharmacodynamic interactions. (1984) (10)
- Drug-drug interactions: Proof of relevance (Part II): cause of tolerability problems or noncompliance. (2005) (9)
- Clinical Relevance of Relative Receptor Binding Affinity: Quetiapine and Ziprasidone as Examples (2007) (9)
- Challenges and opportunities in establishing scientific and regulatory standards for determining therapeutic equivalence of modified-release products: Workshop summary report. (2010) (9)
- Relating clinical trials to psychiatric practice: part II: the gap between the usual patient in registration trials and in practice. (2003) (9)
- Depressive Syndromes in Children and Adolescents: Diagnosis and Treatment (1989) (9)
- Pharmacodynamic and pharmacokinetic factors in a case of neuroleptic malignant syndrome. (1998) (9)
- Drugs Are an Acquired Source of Biological Variance Among Patients (2006) (9)
- Prediction of individual response to antidepressants and antipsychotics: an integrated concept (2014) (9)
- A comparison of the cortisol suppression index and the dexamethasone suppression test in prepubertal children. (1985) (9)
- Tardive Dyskinesia: A Historical Perspective (2017) (9)
- The role of proof of concept (POC) studies in drug development using the EVP-6124 POC study as an example. (2014) (8)
- Depression in children. Effects of antidepressant therapy. (1983) (8)
- Effect of CO2 on a brain extracellular space marker and evidence of its neuronal modulation (1985) (8)
- Clinical pharmacology case conference: a suicide attempt? (2002) (8)
- Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 3: Pharmacokinetic Considerations (2019) (8)
- Analgesic abuse and the barbiturate abstinence syndrome. (1980) (8)
- Letter to the Editor: Clinical versus statistical significance of pharmacogenomic-guided antidepressant therapy: What's really being measured and marketed? (2019) (8)
- Tricyclic antidepressant plasma level monitoring: an improvement over the dose-response approach. (1986) (8)
- Asymmetry in Scientific Method and Limits to Cross-Disciplinary Dialogue (2007) (8)
- Outliers on the dose-response curve: how to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry. (2010) (8)
- Knowledge of the Pharmacology of Antidepressants and Antipsychotics Yields Results Comparable With Pharmacogenetic Testing (2018) (8)
- CNS drug development – Phase III (2010) (8)
- CNS Drug Development: Lessons from the Development of Ondansetron, Aprepitant, Ramelteon, Varenicline, Lorcaserin, and Suvorexant. Part I (2014) (8)
- Flat Dose-Response Curves for Efficacy: What Do They Mean to the Clinician? (2008) (8)
- Declining Differences in Response Rates with Antidepressants versus Placebo: A Modest Proposal for Another Contributing Cause (2013) (8)
- Use of saliva lithium determinations for monitoring lithium therapy. (1978) (8)
- Vilazodone for Major Depressive Disorder (2011) (7)
- The nature and extent of polypharmacy in patients on antidepressants as a function of treatment setting (1999) (7)
- Bupropion: What Mechanism of Action? (2000) (7)
- Neuroscientific Basis of Corticosteroid-Induced Changes in Human Cognitive and Emotional Processing: Implications for Affective Illness (2013) (7)
- COVID-19: Why Has the Mortality Rate Declined? (2020) (7)
- Why Did Terry Fall Off the Dose-Response Curve? (1996) (7)
- Therapeutic drug monitoring of tricyclic antidepressants: a means of avoiding toxicity. (1989) (7)
- Sudden death and tricyclic antidepressants (TCA): A rare adverse event linked to high TCA plasma levels (1993) (7)
- Single dose prediction of steady state plasma levels of amitriptyline. (1982) (7)
- Prospective use of saliva lithium determinations to monitor lithium therapy. (1979) (7)
- CNS Drug Development: Lessons Learned Part 2. Symptoms, Not Syndromes as Targets Consistent with the NIMH Research Domain Approach (2015) (7)
- The Effect of Age on Plasma Levels of Nortriptyline (1991) (7)
- Long-term antidepressant treatment: Alterations in cerebral capillary permeability (1980) (7)
- Challenges and Opportunities in Establishing Scientific and Regulatory Standards for Assuring Therapeutic Equivalence of Modified Release Products: Workshop Summary Report (2010) (7)
- Drug-drug interaction in reverse: possible loss of phenytoin efficacy as a result of fluoxetine discontinuation. (1999) (7)
- The Role of the Central Adrenergic System in the Regulation of the Cerebromicrocirculation a (1986) (7)
- The Recommended Dosage Range: How Is It Established and Why Would It Ever Be Exceeded? (2004) (7)
- Outpatient Management of Depression, 3rd Edition (2010) (7)
- A roadmap to key pharmacologic principles in using antipsychotics: application in clinical practice. (2009) (7)
- Mania in a Case of Polypsychopharmacology: Pharmacodynamic and Pharmacokinetic Considerations Do You Believe in Magic? (2007) (6)
- A modified method for the simultaneous determination of regional single-transit brain extraction of diffusion-limited compounds and cerebral blood flow: Utilization of non-invasive measurement of transit time (1985) (6)
- How Multiple Medication Use Evolves and the Importance of Therapeutic Trials: The Slippery Slide (2008) (6)
- CNS Drug Development, Lessons Learned, Part 5: How Preclinical and Human Safety Studies Inform the Approval and Subsequent Use of a New Drug—Suvorexant as an Example (2018) (6)
- Effects of antidepressants on the cytochrome P450 system. (1996) (6)
- Dose-effect and concentration-effect relationships with new antidepressants. (1993) (6)
- Differential effect of amitriptyline and bupropion on primary and secondary depression: a pilot study. (1988) (6)
- Why Are Patients With COVID-19 at Risk for Drug-Drug Interactions? (2020) (6)
- High false-positive rate of a putative biomarker test to aid in the diagnosis of schizophrenia. (2016) (5)
- What to do about extremely high plasma levels of tricyclics? (1989) (5)
- Pharmacokinetics of intramuscular ziprasidone in schizophrenic patients: Population pharmacokinetic modelling (1998) (5)
- Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data (2016) (5)
- The implication of concentration/response studies of tricyclic antidepressants for psychiatric research and practice. (1984) (5)
- fMRI (2020) (5)
- Targeted pharmacotherapy in depression management (1994) (5)
- A liquid chromatographic method for quantitating amitriptyline in brain tissue (2004) (5)
- Characterization of the intramuscular pharmacokinetics of ziprasidone in schizophrenic patients (1998) (5)
- Drug-drug Interactions in Psychiatric Practice, Part 1: Reasons, Importance, and Strategies to Avoid and Recognize Them. (2018) (5)
- Imipramine, Mirtazapine, and Nefazodone: Multiple Targets (2000) (5)
- Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development. (2019) (5)
- Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 2: Preclinical and Early Phase Human Proof of Concept Studies (2016) (5)
- EVIDENCE FOR CENTRAL ADRENERGIC REGULATION OF CEREBRAL VASCULAR PERMEABILITY AND BLOOD FLOW (1979) (5)
- CNS Drug Development: Lessons Learned Part 3 Psychiatric and Central Nervous System Drugs Developed Over the Last Decade—Implications for the Field (2017) (5)
- Drug development in psychiatry and the human genome project: the explosion in knowledge and potential targets. (2001) (5)
- Single enantiomer drugs: should they be developed? (2006) (5)
- Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 2: Strategies to Minimize Adverse Outcomes From Unintended DDIs. (2018) (5)
- Polypharmacy in a case of refractory major depression: part II: implications for clinical management. (2003) (5)
- Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study. (2007) (4)
- P.3.c.050 Effect of asenapine versus quetiapine and placebo on QTc interval in patients with schizophrenia (2007) (4)
- A descriptive profile of the depressed child. (1989) (4)
- Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 4: Case Report Data (2016) (4)
- 14-131 Sertraline does not inhibit cytochrome P450 (CYP) 3A-mediated drug metabolism in vivo (1997) (4)
- Pharmacokinetics in Child/Adolescent Psychiatric Disorders (1994) (4)
- Factors affecting the biphasic concentration: effect relationships of tricyclic antidepressants (1981) (4)
- Changes in the product label for pimozide illustrate both the promises and the challenges of personalized medicine. (2012) (4)
- CNS Drug Development, Lessons Learned, Part 4: The Role of Brain Circuitry and Genes—Tasimelteon as an Example (2017) (4)
- How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example. (2015) (4)
- Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1 (2015) (4)
- Plasma monitoring of tricyclic antidepressants: defining the therapeutic range for imipramine in depressed children. (1986) (4)
- Ethanol effects on brain concentrations of amitriptyline and the relationship to psychomotor function (2004) (4)
- Switching From the Oral to the Depot Formulation of a Medication: Clinically Relevant Pharmacokinetic Concepts and Considerations (2017) (4)
- Failure of buspirone to protect against lorazepam withdrawal symptoms. (1987) (4)
- Medical Management of the Depressed Alcoholic Patient (1988) (4)
- Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 9: Interactions Mediated by Drug-metabolizing Cytochrome P450 Enzymes (2020) (4)
- Drug-drug Interactions in Psychiatric Practice, Part 4: Classification of Neuropsychiatric Medications Based on Their Principal Mechanisms of Action (With Updated Neuroscience-based Nomenclature). (2019) (4)
- Clinically Relevant Pharmacology of Neuropsychiatric Drugs Approved Over the Last Three Years: Part I (2006) (4)
- Multiple Medication Use in General Practice and Psychiatry: So What? (2005) (4)
- Update on antidepressant therapy. (1994) (4)
- Clinical Psychopharmacology and Medical Malpractice: The Four Ds (2014) (4)
- Use of an Analog Scale in the Treatment of Patients With Major Depressive Disorder to Optimize Assessment and Clinical Outcome (2016) (3)
- PII‐63 (2006) (3)
- The Role of Benzodiazepines in the Treatment of Psychotic Disorders (1993) (3)
- The Relative Adverse Effect Profile of Non-SSRI Antidepressants: Relationship to In Vitro Pharmacology (2000) (3)
- COVID-19: Protecting the vulnerable and opening the economy (2020) (3)
- P-2-17 Sertraline and P4503A3/4 (1996) (3)
- Failure to consider drug-drug interactions as a likely cause of behavioral deterioration in a patient with bipolar disorder. (2000) (3)
- Antidepressant options in primary care. (1999) (3)
- Emsam: the first year. (2007) (3)
- Patient with bipolar disorder and familial QT prolongation: what to do? (2006) (3)
- Mental Health Care Providers Dealing With Coronavirus Disease 2019 (COVID-19): What Is the Definition of a Case, How Is That Changing, and What Kinds of Tests Are Available? (2020) (3)
- Essential CNS Drug Development: Contents (2012) (3)
- D2-blockade and possible ziprasidone-induced galactorrhea. (2005) (3)
- Nootropics (1993) (3)
- Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial. (2022) (3)
- Drug discovery in psychiatry: drilling down on the target of interest. (2001) (3)
- Transgenic Animal (2020) (3)
- Pharmacokinetics of the newer antidepressants. (1996) (3)
- Genetic and Related Laboratory Tests in Psychiatry: What Mental Health Practitioners Need to Know (2016) (3)
- Mechanisms and Interventions in Tricyclic Antidepressant Overdoses (1984) (3)
- Psychopharmacology and Psychotherapy: What's the Connection? (2006) (3)
- How the pharmacokinetics and receptor-binding profile of lurasidone affect the clinical utility and safety of the drug in the treatment of schizophrenia (2015) (2)
- Affective State (2020) (2)
- New Laboratory Tests in Psychiatry: What Should Mental Health Practitioners Know? (2016) (2)
- Two Clinically Important but Underutilized and Misunderstood Tools: Formulas to Estimate Creatinine Clearance and Therapeutic Drug Monitoring (2020) (2)
- Depression in Children: Defining the Therapeutic Range for Imipramine (1989) (2)
- Desvenlafaxine for Depression (2008) (2)
- How and Why Study Designs Affect the Nature and Validity of Study Results: Appearance Versus True Knowledge. Part I (2009) (2)
- Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 7: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antipsychotics (2019) (2)
- Pharmacokinetics (PK) of donepezil and risperidone in males with schizophrenia (2001) (2)
- Use of an Analog Scale in the Treatment of Patients With Bipolar Disorder to Optimize Assessment and Clinical Outcome (2017) (2)
- Personalized Medicine in Psychiatry: Concepts for Bringing Associated Testing Into Clinical Practice. (2016) (2)
- Physician Perceptions of Drug-Drug Interactions and How To Avoid Them (2002) (2)
- Dr Preskorn replies. (2008) (2)
- Behavioral Facilitation (2006) (2)
- How an Understanding of the Function of the Locus Coeruleus Led to Use of Dexmedetomidine to Treat Agitation in Bipolar Disorder: Example of Rational Development of Psychiatric Medications (2022) (2)
- Charting and Handling Therapeutic Drug Monitoring Results: How they Differ From Most Laboratory Results (2021) (2)
- Anxiolytics: Neurochemical, Behavioral, and Clinical Perspectives (1986) (2)
- Essential CNS Drug Development: Phase I trials: from traditional to newer approaches (2012) (2)
- P.2.b.013 A comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine succinate in healthy subjects (2007) (2)
- Use of Population Pharmacokinetic Modeling to Characterize Intramuscular Pharmacokinetics for Ziprasidone in Schizophrenic Patients (1999) (2)
- Nicotine Dependence and Its Treatment (2010) (2)
- Essential CNS Drug Development: History of CNS drug development (2012) (2)
- Inadvertent fatal imipramine poisoning of a child: what happened to Tommy? (2011) (2)
- New Approaches in Translational Medicine for Phase I Clinical Trials of CNS Drugs (2019) (2)
- Pharmacokinetic Principles and Drug Interactions (2003) (2)
- Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression. (2022) (2)
- Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 8: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antidepressants (2020) (2)
- Consistency of the Antidepressant Effect of Intranasal Esketamine in Phase 3 Clinical Trials (2021) (2)
- Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 5: Major Types of Pharmacodynamic DDIs Based on Mechanism of Action (With Updated Neuroscience-based Nomenclature) (2019) (2)
- Outpatient management of the depressed patient. (1995) (1)
- Drug monitoring and improved treatment response. (1980) (1)
- Therapeutic drug monitoring with tricyclic antidepressants: a response. (1994) (1)
- Outliers on the dose-response curve: if the problem is not concentration, then what? (2013) (1)
- CYP enzyme system and its relevance to the pharmacology of sleep (2008) (1)
- P-12-2 The SSRI withdrawal syndrome (1996) (1)
- Assessing the pharmacokinetics of venlafaxine ER 75 mg and desvenlafaxine 50 mg in CYP2D6 extensive and poor metabolizers (2010) (1)
- Charting and Handling Genetic Test Results: How They Differ From Most Laboratory Results (2021) (1)
- 2 Dexmedetomidine Sublingual Film for Acute Agitation in Schizophrenia or Bipolar Disorder by Baseline Clinical Global Impression-Severity of Agitation (2022) (1)
- Sublingual Dexmedetomidine vs Placebo and Acute Agitation Associated With Bipolar Disorder-Reply. (2022) (1)
- Relationship of plasma imipramine levels to CNS toxicity in children. (1988) (1)
- Brattleboro rats exhibit normal Paco2 -induced changes in cerebral microcirculation (1989) (1)
- Comparative Pharmacology of the 3 Marketed Dual Orexin Antagonists—Daridorexant, Lemborexant, and Suvorexant: Part 1: Pharmacokinetic Profiles (2022) (1)
- QTc, the Multitude of Ways It Is Calculated and Implications for Clinical Practice: A Case Example. (2021) (1)
- Treatment of Agitation in Individuals With Bipolar Disorder or Schizophrenia: Lessons Learned for Clinical Psychiatry and Psychiatric Drug Development (2022) (1)
- Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 6: Pharmacodynamic Considerations (2019) (1)
- P.3.c.067 Effect of meal size and fat content on oral ziprasidone absorption (2007) (1)
- Overview of Currently Available Antidepressants (2004) (1)
- Thoughts on the Value of Case Series in the Literature (2023) (1)
- Neuropharmacology of Central Nervous System and Behavioral Disorders (1982) (1)
- National Initiative to Prevent Suicide (NIPS): A New Proposal to Improve the Understanding and Prevention of Suicide (2016) (1)
- Deconstructing a Medication Regimen (2008) (1)
- A stereotaxic implant technique for the weanling rat (1973) (1)
- Asenapine for Schizophrenia and Bipolar I Disorder (2009) (1)
- Attention Deficit Hyperactivity Disorders: Animal Models (2014) (1)
- Consideration of Physiologic Mechanisms in Animal Models of “Sudden Death” (1981) (1)
- Rational use of multiple medications in medicine and psychiatry: a dimensional perspective. (2013) (1)
- Three Clinically Important but Underutilized and Misunderstood Tools: Formulas to Estimate Creatinine Clearance, the Package Insert, and Therapeutic Drug Monitoring. (2019) (1)
- The oral dose-effect relationship for fluvoxamine (1996) (1)
- How and Why Study Designs Affect the Nature and Validity of Study Results: Appearance Versus True Knowledge. Part II (2009) (1)
- Multiple Psychiatric Medications Use in Psychiatry: How Rational Can It Be? (2013) (1)
- Introduction. Pharmacokinetics of psychotropic agents: why and how they are relevant to treatment. (1993) (1)
- P.1.127 The potential for clinically significant drug-drug interactions in patients receiving CYP 2D6 model substrate/drugs and fluoxetine/paroxetine or sertraline (2003) (1)
- SNP (2020) (0)
- Psychology Interns' View of the Psychiatric Consult (1983) (0)
- Reverse Engineering Drugs: Lorcaserin as an Example. (2023) (0)
- Use of plasma levels to avoid amitriptyline toxicity. (1983) (0)
- Cardiac and central nervous system toxicity of antidepressants in relation to drug levels (1993) (0)
- Baclofen-Induced Delirium a Case Report (1990) (0)
- ALDH (2020) (0)
- P-178 Primary care evaluation of mental disorders (PRIME-MD) screening in an urban reproductive medicine clinic (1997) (0)
- DST status and blood chemistries in prepubertal children (1989) (0)
- Subtypes of Major Depressive Disorder Based on Pharmacological Responsiveness. (2021) (0)
- S-60-1 Considerations when using combination drug strategies (1996) (0)
- Use of Laboratory Assessments in Psychiatry (2008) (0)
- Duloxetine (2004) (0)
- Special and Innovative Uses of Benzodiazepines: Introduction and Raison d'être (1993) (0)
- Activities of Daily Living (2021) (0)
- DETAILS TITLE ( PROVISIONAL ) MINOCYCLINE AND ASPIRIN IN THE TREATMENT OF BIPOLAR DEPRESSION : a randomized , double-blind , placebo-controlled , parallel-group clinical trial (2012) (0)
- A Precautionary Tale in Psychiatry (2007) (0)
- Can the Publication of Case Series or Case Reports Lead to a Change in Clinical Practice? (2023) (0)
- P-12-1 Minimum effective doses of SSRIs (1996) (0)
- Separated (2020) (0)
- NREM Sleep (0)
- Evaluation of amitriptyline use for depression when prescribed by internists and psychiatrists. (1984) (0)
- Children and Adolescents (2004) (0)
- Psychotropic drugs and alcohol (1984) (0)
- The deadliest rupture: idiopathic muscular hypertrophy of the esophagus. (1977) (0)
- Fundamental Pharmacokinetic Concepts and Their Clinical Relevance: Clearance, Zero Versus First Order and Nonlinear Pharmacokinetics (2021) (0)
- Pharmacogenetics of Psychotropic Drugs: Methodological issues in psychopharmacogenetics (2002) (0)
- Avoiding SRI Discontinuation Syndrome (2011) (0)
- Addressing Critical Questions About COVID-19 (2020) (0)
- Dexmedetomidine Orally Dissolving Film for Acute Agitation Associated with Schizophrenia or Bipolar Disorder: SERENITY I and SERENITY II Trials (2022) (0)
- PMH7 LIKELIHOOD OF POTENTIAL DRUG-DRUG INTERACTIONS AMONG PERSONS INITIATING THERAPY WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS: EFFECT OF INITIAL SSRI AND OTHER FACTORS (2011) (0)
- National initiative to prevent suicide: a new proposal to improve the understanding and prevention of suicide: analyzing biological samples from suicide victims could yield valuable data for researchers (2016) (0)
- The potential for clinically significant drug‐drug interactions in patients receiving CYP 2D6 model substrate/drugs and fluoxetine/paroxetine or sertraline (2004) (0)
- Discovery of New Transmitter Systems and Hence New Drug Targets. (2023) (0)
- Essential CNS Drug Development: Plate Section (2012) (0)
- Use of Laboratory in Psychiatry (2016) (0)
- 39.4 A DOUBLE-BLIND TRIAL OF VALACYCLOVIR TO IMPROVE COGNITION IN EARLY PHASE SCHIZOPHRENIA: RESULTS FROM THE VISTA STUDY (2018) (0)
- Books Received (2007) (0)
- Comparative Pharmacology of the 3 Marketed Dual Orexin Antagonists—Daridorexant, Lemborexant, and Suvorexant—Part 2. Principal Drug Metabolizing Enzyme, Drug-Drug Interactions, and Effects of Liver and Renal Impairment on Metabolism (2023) (0)
- P-12-33 Polypharmacy: What is its role in the long-term use of antidepressants? (1996) (0)
- Altered acetylcholinesterase activity (AChE) and maze performance of developing rats (Rattus norvegicus) following mesencephalic electrical brain stimulation (1978) (0)
- An Individual With 2 Distinct Nonpathologic Identities. (2022) (0)
- P.1.010 Pharmacology and the relevance for choice (1996) (0)
- Reply to Comments by Dr Hashimoto (2009) (0)
- Introduction: Psychopharmacology-Present and future (1990) (0)
- The Development and Use of Modern Psychotherapeutic Medications (2008) (0)
- Role of Pharmacogenetics/Pharmacogenomics in the Development of New Antidepressants (2004) (0)
- The roadmap for antipsychotic psychopharmacology: an overview. (2007) (0)
- The impact of total calories and fat content on steady-state serum ziprasidone concentrations in patients receiving oral ziprasidone (2007) (0)
- Treatment of Depressive Disorders in Elderly Complicated with Medical Co‐Morbidities and Multiple Medication Use (2009) (0)
- 2004 GuidetoPsychiatric Drug Interactions (2004) (0)
- Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development. (2023) (0)
- What is an animal model ? (2005) (0)
- How Loading Dose Strategies for Depot Paliperidone Can Go Wrong. (2022) (0)
- Reply to "Intrinsic Activity of Aripiprazole Is Not 30% of Dopamine, But Only About 6% Under Ideal Antipsychotic Therapy" (2008) (0)
- New Evidence and Caution (2009) (0)
- Poster #T259 HIGH FALSE POSITIVE RATE OF A PUTATIVE BIOMARKER TEST TO AID IN THE DIAGNOSIS OF SCHIZOPHRENIA (2014) (0)
- P.1.097 The clinical relevance of the cytochrome P450 enzyme system to antidepressants (1997) (0)
- CARDIOVASCULAR AND CENTRAL NERVOUS SYSTEM TOXICITY OF ANTIDEPRESSANTS (1992) (0)
- P.2.c.037 Assessing the pharmacokinetics of venlafaxine er 75 mg and desvenlafaxine 50 mg in CYP2D6 extensive and poor metabolisers (2009) (0)
- SAT-3-2 Pharmacotherapeutic profile of venlafaxine (1995) (0)
- Tricyclic antidepressants: clinical use of plasma levels. (1981) (0)
- Coronavirus Disease 2019: The First Wave and Beyond (2020) (0)
- Building a Comprehensive Biopsychosocial Database to Identify Underlying Causes of Suicide and Improve Suicide Prevention (2022) (0)
- Drug Development : Lessons Learned Part 2 . Symptoms , Not Syndromes as Targets Consistent with the NIMH Research Domain Approach Psychopharmacology (0)
- Plasma Monitoring of Antidepressants (1985) (0)
- Psychopharmacology and Psychotherapy : What ’ s the Connection ? Psychopharmacology (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Sheldon H. Preskorn?
Sheldon H. Preskorn is affiliated with the following schools:
